HK1260327A1 - 檢測癌症復發的方法 - Google Patents

檢測癌症復發的方法

Info

Publication number
HK1260327A1
HK1260327A1 HK19100001.6A HK19100001A HK1260327A1 HK 1260327 A1 HK1260327 A1 HK 1260327A1 HK 19100001 A HK19100001 A HK 19100001A HK 1260327 A1 HK1260327 A1 HK 1260327A1
Authority
HK
Hong Kong
Prior art keywords
methods
cancer recurrence
detecting cancer
detecting
recurrence
Prior art date
Application number
HK19100001.6A
Other languages
English (en)
Inventor
Robyn Lindley
Original Assignee
Gmdx Co Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903456A external-priority patent/AU2015903456A0/en
Application filed by Gmdx Co Pty Ltd filed Critical Gmdx Co Pty Ltd
Publication of HK1260327A1 publication Critical patent/HK1260327A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK19100001.6A 2015-08-26 2019-01-02 檢測癌症復發的方法 HK1260327A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015903456A AU2015903456A0 (en) 2015-08-26 Methods of detecting cancer recurrence
PCT/AU2016/050799 WO2017031551A1 (en) 2015-08-26 2016-08-26 Methods of detecting cancer recurrence

Publications (1)

Publication Number Publication Date
HK1260327A1 true HK1260327A1 (zh) 2019-12-20

Family

ID=58099416

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100001.6A HK1260327A1 (zh) 2015-08-26 2019-01-02 檢測癌症復發的方法

Country Status (8)

Country Link
US (1) US11225690B2 (zh)
EP (1) EP3341496B1 (zh)
JP (1) JP6850294B2 (zh)
CN (2) CN116574809A (zh)
AU (1) AU2016310415B2 (zh)
ES (1) ES2873841T3 (zh)
HK (1) HK1260327A1 (zh)
WO (1) WO2017031551A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031551A1 (en) 2015-08-26 2017-03-02 Gmdx Co Pty Ltd Methods of detecting cancer recurrence
WO2018039567A1 (en) 2016-08-25 2018-03-01 Nantomics, Llc Immunotherapy markers and uses therefor
AU2018367925A1 (en) 2017-11-17 2020-07-02 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
CN108796077B (zh) * 2018-05-30 2021-11-09 朱运峰 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒
US20230242992A1 (en) * 2020-06-01 2023-08-03 Gmdx Co Pty Ltd Methods of predicting cancer progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
AU2013337616B2 (en) * 2012-11-05 2019-03-21 Gmdx Co Pty Ltd Methods for determining the cause of somatic mutagenesis
WO2017031551A1 (en) 2015-08-26 2017-03-02 Gmdx Co Pty Ltd Methods of detecting cancer recurrence

Also Published As

Publication number Publication date
JP6850294B2 (ja) 2021-03-31
CN108603231A (zh) 2018-09-28
EP3341496A1 (en) 2018-07-04
US11225690B2 (en) 2022-01-18
EP3341496A4 (en) 2019-03-27
AU2016310415A1 (en) 2018-04-19
ES2873841T3 (es) 2021-11-04
AU2016310415B2 (en) 2022-04-21
WO2017031551A1 (en) 2017-03-02
JP2018531620A (ja) 2018-11-01
CN116574809A (zh) 2023-08-11
EP3341496B1 (en) 2021-02-24
CN108603231B (zh) 2023-06-30
US20200232038A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
GB201618485D0 (en) Method of detecting tumour recurrence
HK1253314A1 (zh) 染色體互相作用的檢測
EP3443066A4 (en) EARLY DETECTION METHODS FOR CANCER
HK1246828A1 (zh) 用於檢測癌症的生物標志物組
IL240153B (en) Line of block detection
HK1232139A1 (zh) 生物標誌物指導的多靶向免疫治療
HK1251414A1 (zh) 用於檢測癌症復發風險的方法和組合物
HK1260327A1 (zh) 檢測癌症復發的方法
IL251141B (en) A method for predicting the risk of cancer recurrence
HK1213634A1 (zh) 檢測癌症的方法
GB201415761D0 (en) Methods for detection of Nucleotide modification
GB201602210D0 (en) Detection of cancer
EP3183578B8 (en) Methods for the early detection of colorectal cancer
SG11201701875YA (en) Methods for detecting ovarian cancer
SG10201913528PA (en) Methods of diagnosing cancer
EP3191846A4 (en) Methods of detecting prostate cancer
EP3298172A4 (en) Determining risk of prostate cancer recurrence
IL257514A (en) A method for detecting cancer
IL247270B (en) A method for detecting cancer
SG11201702077RA (en) Kit for cancer detection
EP3189332A4 (en) Biomarkers for detection of breast cancer
GB201508480D0 (en) Cancer
HK1250582A1 (zh) 癌症標誌物pd-ecgf
IL248126A0 (en) Combinations of cancer treatments
EP3183366A4 (en) Systems and methods of detecting solid tumor cancer